Consultant lobbyist
Mirianna Georges
Santis Health
- Meetings this Parliament
- 15
- Since Nov 2021
- 15
- Active registrations
- 0
Mirianna Georges's lobbying: the clients they represent and every meeting they've reported since November 2021.
← LobbyingCurrent clients
No registration in effect right now.
Earlier, since November 2021
- Best Medicines Coalition 13 · last Jul 28, 2026
- Breakthrough T1D 1 · last Apr 20, 2026
- Breast Cancer Canada 1 · last Mar 20, 2026
Reported meetings
-
- Justine Frame · Policy Advisor, Health Canada (HC)
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency. Read more
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Provide input on a national strategy for drugs for rare diseases.
Provide input on pharmacare.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
Support input into the consultation on draft guidance on decentralized clinical trials.
Recommend the creation of a Chief Patient Officer.
Support input regarding Canada’s pharmaceutical sovereignty.
Recommend the creation of a Patient Ombudsman.
-
- Matt Strauss · Member of Parliament
Recommend the creation of a Chief Patient Officer. Read more
Provide input on pharmacare.
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Provide input on a national strategy for drugs for rare diseases.
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Support input into the consultation on draft guidance on decentralized clinical trials.
Recommend the creation of a Patient Ombudsman.
Support input regarding Canada’s pharmaceutical sovereignty.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
-
- Nasser Haider · Senior Policy Advisor, Finance Canada (FIN)
Provide input on pharmacare. Read more
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Provide input on a national strategy for drugs for rare diseases.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Recommend the creation of a Patient Ombudsman.
Support input regarding Canada’s pharmaceutical sovereignty.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Recommend the creation of a Chief Patient Officer.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Support input into the consultation on draft guidance on decentralized clinical trials.
-
- Anita Anand · MP
- Ben Carr · MP
- Maggie Chi · Member of Parliament
- Raquel Dancho · Member of Parliament
and 13 moreShow fewer
- Sean Fraser · Minister of Justice and Attorney General of Canada
- Tom Kmiec · Member of Parliament
- Joël Lightbound · Member of Parliament
- Jennifer McKelvie · Member of Parliament
- Anna Roberts · Member of Parliament
- Sonia Sidhu · Member of Parliament
- Gigi Osler · Senator, Senate of Canada
- Jim Quinn · Senator, Senate of Canada
- Colin Deacon · Senator, Senate of Canada
- Ravalia Mohamed-Iqbal · Senator, Senate of Canada
- Stan Kutcher · Senator, Senate of Canada
- Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
Supporting engagement on the value in curing type one diabetes across Canada by seeking funding for increased and innovative research.
-
- Maxime Blanchette-Joncas · Member of Parliament
Provide input on pharmacare. Read more
Recommend the creation of a Chief Patient Officer.
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Provide input on a national strategy for drugs for rare diseases.
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Support input regarding Canada’s pharmaceutical sovereignty.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Recommend the creation of a Patient Ombudsman.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
Support input into the consultation on draft guidance on decentralized clinical trials.
-
- Tom Kmiec · Member of Parliament
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States. Read more
Provide input on a national strategy for drugs for rare diseases.
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
Recommend the creation of a Chief Patient Officer.
Provide input on pharmacare.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Recommend the creation of a Patient Ombudsman.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Support input regarding Canada’s pharmaceutical sovereignty.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Support input into the consultation on draft guidance on decentralized clinical trials.
-
- Dan Mazier · Member of Parliament
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines. Read more
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Provide input on a national strategy for drugs for rare diseases.
Provide input on pharmacare.
Recommend the creation of a Chief Patient Officer.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Recommend the creation of a Patient Ombudsman.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
Support input into the consultation on draft guidance on decentralized clinical trials.
Support input regarding Canada’s pharmaceutical sovereignty.
-
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Senior Director, Office of Life Sciences and Biomanufacturing Readiness, Innovation Science and Economic Development Canada, Innovation, Science and Economic Development Canada (ISED)
- Jasmine Hamilton · Senior Advisor, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency. Read more
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Recommend the creation of a Patient Ombudsman.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Provide input on pharmacare.
Provide input on a national strategy for drugs for rare diseases.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Recommend the creation of a Chief Patient Officer.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Support input into the consultation on draft guidance on decentralized clinical trials.
Support input regarding Canada’s pharmaceutical sovereignty.
-
- David Lee · Chief Regulatory Officer, Health Products and Food Branch, Health Canada (HC)
- Bruno Rodrigue · Executive Director, Office of Legislative and Regulatory Modernization, Health Canada (HC)
- Kelly Robinson · Executive Director, Office of Legislative and Regulatory Modernization, Health Canada (HC)
Provide input on pharmacare. Read more
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Recommend the creation of a Patient Ombudsman.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
Provide input on a national strategy for drugs for rare diseases.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Recommend the creation of a Chief Patient Officer.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Support input into the consultation on draft guidance on decentralized clinical trials.
Support input regarding Canada’s pharmaceutical sovereignty.
-
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency. Read more
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Provide input on pharmacare.
Support input regarding Canada’s pharmaceutical sovereignty.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Recommend the creation of a Chief Patient Officer.
Provide input on a national strategy for drugs for rare diseases.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Recommend the creation of a Patient Ombudsman.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
Support input into the consultation on draft guidance on decentralized clinical trials.
-
- Sonia Sidhu · Member of Parliament
Provide input on pharmacare. Read more
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Provide input on a national strategy for drugs for rare diseases.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Recommend the creation of a Chief Patient Officer.
Support input regarding Canada’s pharmaceutical sovereignty.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Support input into the consultation on draft guidance on decentralized clinical trials.
Recommend the creation of a Patient Ombudsman.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
-
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones. Read more
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Support input regarding Canada’s pharmaceutical sovereignty.
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Provide input on a national strategy for drugs for rare diseases.
Recommend the creation of a Chief Patient Officer.
Provide input on pharmacare.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Recommend the creation of a Patient Ombudsman.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
Support input into the consultation on draft guidance on decentralized clinical trials.
-
- Maggie Chi · Member of Parliament
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States. Read more
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Provide input on pharmacare.
Support input regarding Canada’s pharmaceutical sovereignty.
Provide input on a national strategy for drugs for rare diseases.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Support input into the consultation on draft guidance on decentralized clinical trials.
-
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Provide input on pharmacare. Read more
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Provide input on a national strategy for drugs for rare diseases.
Support input regarding Canada’s pharmaceutical sovereignty.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Support input into the consultation on draft guidance on decentralized clinical trials.
-
- Danièle Henkel · Senator, Senate of Canada
Regulations and guidelines affecting women's health like breast cancer screening, access to innovative technology and precision medicine.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.